1,3-Dioxolane, 2-(bromomethyl)- → 4-bromo-3-[4-(1-[1,3]dioxolan-2-ylmethyl-1H-indol-3-yl)-piperidin-1-ylmethyl]-benzoic Acid
反応式
C[O:2][C:3](=[O:27])[C:4]1[CH:9]=[CH:8][C:7]([Br:10])=[C:6]([CH2:11][N:12]2[CH2:17][CH2:16][CH:15]([C:18]3[C:26]4[C:21](=[CH:22][CH:23]=[CH:24][CH:25]=4)[NH:20][CH:19]=3)[CH2:14][CH2:13]2)[CH:5]=1.Br[CH2:29][CH:30]1[O:34][CH2:33][CH2:32][O:31]1>>[Br:10][C:7]1[CH:8]=[CH:9][C:4]([C:3]([OH:2])=[O:27])=[CH:5][C:6]=1[CH2:11][N:12]1[CH2:13][CH2:14][CH:15]([C:18]2[C:26]3[C:21](=[CH:22][CH:23]=[CH:24][CH:25]=3)[N:20]([CH2:29][CH:30]3[O:34][CH2:33][CH2:32][O:31]3)[CH:19]=2)[CH2:16][CH2:17]1参加物
3
実験手順
This compound was prepared following the procedure described in example 1 (part E) starting with 0.055 g (0.13 mmol) 4-bromo-3-[4-(1H-indol-3-yl)-piperidin-1-ylmethyl]-benzoic acid methyl ester and 0.034 mg (0.16 mmol) 2-bromomethyl-[1,3]dioxolane. After the described purification, 0.021 g (32% of yield) of the expected acid was obtained.
後処理
- customThis compound was prepared
- customAfter the described purification, 0.021 g (32% of yield) of the expected acid